Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

0.8378 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 0.8378
Bid (Size) 0.7830 (25)
Ask (Size) 0.8500 (64)
Prev. Close 0.8378
Today's Range 0.8378 - 0.8378
52wk Range 0.6746 - 2.715
Shares Outstanding 72,407,215
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. 
Via InvestorPlace

Performance

YTD
-11.81%
-11.81%
1 Month
-8.94%
-8.94%
3 Month
-9.58%
-9.58%
6 Month
+10.38%
+10.38%
1 Year
-66.35%
-66.35%

More News

Read More
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
Via InvestorPlace
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Analyst Expectations for Kezar Life Sciences's Future
Via Benzinga
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Via Talk Markets
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
Via InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Via InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
Via InvestorPlace
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
From Kezar Life Sciences, Inc.
Via Business Wire
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Via Talk Markets
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.